- Conditions
- Peanut Hypersensitivity
- Interventions
- Peanut Oral Immunotherapy, Omalizumab
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced May 21, 2026, 9:50 PM EDT